Akeso, Summit cancer drug confirms lung cancer survival benefit

Data ReadoutpositiveivonescimabKeytrudaPositive

AI Analysis

Summary

Akeso and Summit's ivonescimab, a bispecific antibody, demonstrated superior survival benefit compared to Merck's Keytruda in a new lung cancer trial data cut.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

ivonescimab demonstrated survival benefit compared to Keytruda in lung cancer trial

Importance:7/10

Sentiment:

0.75

oncologybispecific antibodylung cancerclinical trialsurvival benefit

Related Companies

$MRK

Read the original article

Published by BioPharma Dive on September 3, 2026 1:14 PM

Read Original